Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease

31 Jul 2024

Abstract excerpt

Sickle cell disease is a growing health burden afflicting millions around the world. Clinical observation and laboratory studies have shown that the severity of sickle cell disease is ameliorated in individuals who have elevated levels of fetal hemoglobin. Additional pharmacologic agents to induce sufficient fetal hemoglobin to diminish clinical severity is an unmet medical need. We recently found that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone and Joint Diseases
Share to Hemoglobinopathies and Related Disorders
Share to Peroxisome Proliferator-Activated Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39083598
DOI: 10.1126/sciadv.adn8750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell diseasePMID 39083598Read ↗

Elevating fetal hemoglobin: recently discovered regulators and mechanismsSemantic proximity Read ↗

Salubrinal induces fetal hemoglobin expression via the stress-signaling pathway in human sickle erythroid progenitors and sickle cell disease miceSemantic proximity Read ↗

Targeting fetal hemoglobin expression to treat β hemoglobinopathiesSemantic proximity Read ↗

Recent Advances in the Treatment of Sickle Cell DiseaseSemantic proximity Read ↗

Innovations in Drug Discovery for Sickle Cell Disease Targeting Oxidative Stress and NRF2 Activation – A Short ReviewSemantic proximity Read ↗

Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sicklingSemantic proximity Read ↗

Pharmacologic induction of <scp>PGC</scp>‐1α stimulates fetal haemoglobin gene expressionSemantic proximity Read ↗

Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editingSemantic proximity Read ↗

NRF2 mediates γ-globin gene regulation and fetal hemoglobin induction in human erythroid progenitorsSemantic proximity Read ↗

Hope on the Horizon: New and Future Therapies for Sickle Cell DiseaseSemantic proximity Read ↗

Genomic discovery and functional validation of MRP1 as a novel fetal hemoglobin modulator and potential therapeutic target in sickle cell diseaseSemantic proximity Read ↗

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated PerspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.